Brain+
0.01 DKK
-10.26 %
Less than 1K followers
BRAINP
First North Denmark
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Brain+
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Revenue | 6.7 | 4.0 | 0.2 | ||
| growth-% | -40.3 % | ||||
| EBITDA | 0.2 | -5.7 | -9.5 | -8.7 | -8.2 |
| EBIT | -1.4 | -7.3 | -11.1 | -17.5 | -11.7 |
| Profit before taxes | -16.4 | -9.1 | -11.1 | -19.8 | -12.5 |
| Net income | -1.3 | -7.1 | -9.7 | -19.1 | -12.1 |
| EPS | -0.03 | -0.19 | -0.19 | -0.24 | -0.04 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| EBITDA-% | 2.9 % | -141.8 % | -4,075.0 % | ||
| EBIT-% | -21.1 % | -182.0 % | -5,830.0 % | ||
| ROE | -66.6 % | -34.4 % | -59.1 % | -154.4 % | -109.7 % |
| ROI | -4.3 % | -15.1 % | -21.3 % | -53.2 % | -36.4 % |